Livzon Pharmaceutical Group Dirección

Dirección controles de criterios 4/4

El CEO de Livzon Pharmaceutical Group's es Yanggang Tang , nombrado en Dec 2018, tiene una permanencia de 5.33 años. compensación anual total es CN¥581.00K, compuesta por 19.1% salario y 80.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.037% de las acciones de la empresa, por valor de CN¥11.89M. La antigüedad media del equipo directivo y de la junta directiva es de 9.8 años y 4.8 años, respectivamente.

Información clave

Yanggang Tang

Chief Executive Officer (CEO)

CN¥581.0k

Compensación total

Porcentaje del salario del CEO	19.1%
Permanencia del CEO	5.4yrs
Participación del CEO	0.04%
Permanencia media de la dirección	9.9yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yanggang Tang en comparación con los beneficios de Livzon Pharmaceutical Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥581k	CN¥111k	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥520k	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Jan 01 2022	n/a	n/a	CN¥2b
Sep 30 2021	n/a	n/a	CN¥2b
Jun 30 2021	n/a	n/a	CN¥2b
Mar 31 2021	n/a	n/a	CN¥2b
Jan 01 2021	n/a	n/a	CN¥2b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥2b
Mar 31 2020	n/a	n/a	CN¥1b
Jan 01 2020	n/a	n/a	CN¥1b
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥3m	CN¥800k	CN¥1b

Compensación vs. Mercado: La compensación total de Yanggang($USD80.19K) está por debajo de la media de empresas de tamaño similar en el mercado CN ($USD209.32K).

Compensación vs. Ingresos: La compensación de Yanggang ha sido consistente con los resultados de la empresa en el último año.

CEO

Yanggang Tang (53 yo)

5.4yrs

Permanencia

CN¥581,000

Compensación

Mr. Yanggang Tang has been President of Livzon Pharmaceutical Group since December 28, 2018 and serves as its Executive Director since February 14, 2019 and served as its Executive Vice President from July...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yanggang Tang	President & Executive Director	5.4yrs	CN¥581.00k	0.037% CN¥ 12.1m
Guoxiang Xu	Executive Vice Chairman & VP of Sales	6.9yrs	CN¥547.19k	0.085% CN¥ 27.5m
Yanxia Si	VP & CFO	9.9yrs	CN¥354.39k	0.044% CN¥ 14.2m
Liang Yang	VP, Secretary to the Board & Company Secretary	9.9yrs	CN¥235.72k	0.022% CN¥ 7.1m
Daihong Yang	Vice President	18yrs	CN¥371.99k	0.051% CN¥ 16.4m
Yuxuan Huang	Vice President	5.6yrs	CN¥239.24k	0.015% CN¥ 4.7m
Jun Du	Vice President	less than a year	CN¥516.55k	0.0054% CN¥ 1.8m
Jianing Liu	Chief Investment Officer & Head of BD Dept.	no data	sin datos	sin datos
Jianying Zhuang	Head of Accounting Department	no data	sin datos	sin datos
Maolin Wang	Chief Supervisor and GM of Legal & Compliance	23.3yrs	CN¥353.10k	sin datos
Daping Liu	Vice President	less than a year	sin datos	sin datos

9.9yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000513 es experimentado (9.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yanggang Tang	President & Executive Director	5.3yrs	CN¥581.00k	0.037% CN¥ 12.1m
Guoxiang Xu	Executive Vice Chairman & VP of Sales	6.9yrs	CN¥547.19k	0.085% CN¥ 27.5m
Maolin Wang	Chief Supervisor and GM of Legal & Compliance	14.3yrs	CN¥353.10k	sin datos
Qingfeng Qiu	Non-Executive Director	17.1yrs	CN¥9.60k	sin datos
Baoguo Zhu	Non-Executive Chairman of the Board	21.9yrs	CN¥325.00k	0% CN¥ 0
Desheng Tao	Non-Executive Vice Chairman	14.8yrs	CN¥300.00k	0.080% CN¥ 25.7m
Xiong Yu	Non-Executive Director	3.9yrs	CN¥9.60k	sin datos
Qiusheng Tian	Independent Non-Executive Director	4.6yrs	CN¥12.00k	sin datos
Hua Bai	Independent Non-Executive Director	3.9yrs	CN¥12.00k	sin datos
Huiyuan Luo	Independent Non-Executive Director	2.8yrs	CN¥12.00k	sin datos
Kam Wa Wong	Independent Non-Executive Director	4.6yrs	CN¥12.00k	sin datos
Lijie Cui	Independent Non-Executive Director	2.8yrs	CN¥12.00k	sin datos

4.9yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 000513 se considera experimentada (4.8 años de antigüedad promedio).

Livzon Pharmaceutical Group Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Recent updates

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Price target decreased to CN¥42.19

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings: EPS misses analyst expectations

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

President & Executive Director exercised options to buy CN¥2.7m worth of stock.

New 90-day low: CN¥46.34

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings beat expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2020 Results on Oct 23, 2020

Price target raised to CN¥51.22

Earnings released

Livzon Pharmaceutical Group Inc. to Report First Half, 2020 Results on Aug 26, 2020

New 90-day high - CN¥56.12

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media